Latest Articles

Publication Date
All News Scientific
Onconic's Nesuparib Targets 26 Trillion Won Endometrial Cancer Market, Backed by SCI Paper - Seoul Economic Daily

Onconic's Nesuparib Targets 26 Trillion Won Endometrial Cancer Market, Backed by SCI Paper Seoul Economic Daily

Published: July 16, 2026, 5:33 a.m.
Read Full Article
Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype - londoninsider.co.uk

Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype londoninsider.co.uk

Published: July 15, 2026, 11:49 p.m.
Read Full Article
Merck touts Keytruda front-line win in endometrial cancer subtype, marking a PD-1 first - Fierce Pharma

Merck touts Keytruda front-line win in endometrial cancer subtype, marking a PD-1 first Fierce Pharma

Published: July 15, 2026, 7:33 p.m.
Read Full Article
Merck posts late-stage trial win for frontline Keytruda in endometrial cancer - MSN

Merck posts late-stage trial win for frontline Keytruda in endometrial cancer MSN

Published: July 15, 2026, 6:22 p.m.
Read Full Article
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer - Benzinga

Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer Benzinga

Published: July 15, 2026, 5:25 p.m.
Read Full Article
GSK Advances New Maintenance Therapy Trial in Endometrial Cancer, Adding Depth to Its Oncology Pipeline - TipRanks

GSK Advances New Maintenance Therapy Trial in Endometrial Cancer, Adding Depth to Its Oncology Pipeline TipRanks

Published: July 15, 2026, 4:46 p.m.
Read Full Article
Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer - OncLive

Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer OncLive

Published: July 15, 2026, 3:58 p.m.
Read Full Article
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - BioSpace

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy BioSpace

Published: July 15, 2026, 3:11 p.m.
Read Full Article
Merck's KEYTRUDA trial may offer a chemo-free option in endometrial cancer - Stock Titan

Merck's KEYTRUDA trial may offer a chemo-free option in endometrial cancer Stock Titan

Published: July 15, 2026, 10:48 a.m.
Read Full Article
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - Business Wire

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy Business Wire

Published: July 15, 2026, 10:45 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!